Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Autor: Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Jansen van Rensburg, J. H., Rex, J. H., Lau, W., Facklam, D., Buell, D. N.

Publikováno v: European Journal of Clinical Microbiology & Infectious Diseases; Oct2005, Vol. 24 Issue 10, p654-661, 8p

Clinical Oncology Program: a community cancer control model.

Autor: Dugan, W. M., Minnick, D. J., Wood, J. R., Dailey, K. S., Jansen, M. A., Lohrman, R. G., Buell, D. N., Dugan, W M Jr

Publikováno v: CA: A Cancer Journal for Clinicians; Sep/Oct1979, Vol. 29 Issue 5, p300-305, 6p

Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.

Autor: Roseboom IC; Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Rosing H; Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Dorlo TPC; Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Publikováno v: Biomedical chromatography : BMC [Biomed Chromatogr] 2023 Jul; Vol. 37 (7), pp. e5519. Date of Electronic Publication: 2022 Nov 04.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

Autor: Ratanatharathorn, V., Nash, R. A., Przepiorka, D., Devine, S. M., Klein, J. L., Weisdorf, D., Fay, J. W., Nademanee, A., Antin, J. H., Christiansen, N. P., Jagt, R., Herzig, R. H., Litzow, M. R., Wolff, S. N., Longo, W. L., Petersen, F. B., Karanes, C., Avalos, B., Storb, R., Buell, D. N., Maher, R. M., Fitzsimmons, W. E., John Wingard

Publikováno v: Dimensions

We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling marrow transplantation in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7e610a9fbb7fc93231a3798d58f4bc9b
https://app.dimensions.ai/details/publication/pub.1083319625